

Virginie Marcel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6968649/publications.pdf>

Version: 2024-02-01

48
papers

2,739
citations

201575

27
h-index

189801

50
g-index

54
all docs

54
docs citations

54
times ranked

4203
citing authors

#	ARTICLE	IF	CITATIONS
1	Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance. Nature Communications, 2022, 13, 173.	5.8	23
2	Heterogeneity and dynamic of EMT through the plasticity of ribosome and mRNA translation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188718.	3.3	8
3	Low level of Fibrillarlin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer. BMC Cancer, 2022, 22, 526.	1.1	10
4	Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancerâ€”A CLIPP program INCA in collaboration with GINECO group.. Journal of Clinical Oncology, 2021, 39, 5507-5507.	0.8	5
5	A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate. NAR Cancer, 2021, 3, zcab032.	1.6	22
6	2â€²-O-Ribose Methylation of Ribosomal RNAs: Natural Diversity in Living Organisms, Biological Processes, and Diseases. Cells, 2021, 10, 1948.	1.8	13
7	Ribosome Biogenesis Alterations in Colorectal Cancer. Cells, 2020, 9, 2361.	1.8	28
8	Iron and hepcidin mediate human colorectal cancer cell growth. Chemo-Biological Interactions, 2020, 319, 109021.	1.7	33
9	snoRNAs Offer Novel Insight and Promising Perspectives for Lung Cancer Understanding and Management. Cells, 2020, 9, 541.	1.8	41
10	Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1. Cells, 2020, 9, 941.	1.8	3
11	Ribosomal RNA 2â€²-O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. NAR Cancer, 2020, 2, zcaa036.	1.6	40
12	Analysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot study. Advances in Clinical and Experimental Medicine, 2020, 29, 107-113.	0.6	12
13	Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. Molecular Cell, 2019, 73, 1162-1173.e5.	4.5	81
14	Emerging Role of Eukaryote Ribosomes in Translational Control. International Journal of Molecular Sciences, 2019, 20, 1226.	1.8	49
15	Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics. Biochemical Pharmacology, 2019, 159, 74-81.	2.0	109
16	The Nonstructural NS1 Protein of Influenza Viruses Modulates <i>TP53</i> Splicing through Host Factor CPSF4. Journal of Virology, 2019, 93, .	1.5	21
17	Externalized Keratin 8: A Target at the Interface of Microenvironment and Intracellular Signaling in Colorectal Cancer Cells. Cancers, 2018, 10, 452.	1.7	2
18	2â€²-O-Methylation of Ribosomal RNA: Towards an Epitranscriptomic Control of Translation?. Biomolecules, 2018, 8, 106.	1.8	88

#	ARTICLE	IF	CITATIONS
19	Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes. <i>Cancers</i> , 2018, 10, 390.	1.7	12
20	40 Years of Research Put p53 in Translation. <i>Cancers</i> , 2018, 10, 152.	1.7	43
21	Evidence for rRNA 2â€²-O-methylation plasticity: Control of intrinsic translational capabilities of human ribosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12934-12939.	3.3	197
22	Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. <i>PLoS ONE</i> , 2017, 12, e0170160.	1.1	25
23	Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. <i>Oncotarget</i> , 2017, 8, 46219-46233.	0.8	25
24	Ribosome heterogeneity in tumorigenesis: the rRNA point of view. <i>Molecular and Cellular Oncology</i> , 2015, 2, e983755.	0.3	34
25	p53, a translational regulator: contribution to its tumour-suppressor activity. <i>Oncogene</i> , 2015, 34, 5513-5523.	2.6	71
26	Ribosomal RNA Methylation and Cancer. , 2015, , 115-139.		4
27	Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts. <i>Carcinogenesis</i> , 2014, 35, 2706-2715.	1.3	25
28	Modulation of p53 ^{Î²} and p53 ^{Î³} expression by regulating the alternative splicing of TP53 gene modifies cellular response. <i>Cell Death and Differentiation</i> , 2014, 21, 1377-1387.	5.0	80
29	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. <i>Carcinogenesis</i> , 2014, 35, 807-815.	1.3	29
30	p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer. <i>Cancer Cell</i> , 2013, 24, 318-330.	7.7	246
31	Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a. <i>Journal of General Virology</i> , 2013, 94, 985-995.	1.3	76
32	Detecting and Quantifying p53 Isoforms at mRNA Level in Cell Lines and Tissues. <i>Methods in Molecular Biology</i> , 2013, 962, 1-14.	0.4	14
33	Detecting p53 Isoforms at Protein Level. <i>Methods in Molecular Biology</i> , 2013, 962, 15-29.	0.4	17
34	A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. <i>Cell Death and Disease</i> , 2013, 4, e492-e492.	2.7	43
35	Ribosomes: the future of targeted therapies?. <i>Oncotarget</i> , 2013, 4, 1554-1555.	0.8	11
36	Influenza A Viruses Control Expression of Proviral Human p53 Isoforms p53 ^{Î²} and p53 ^{Î³} . <i>Journal of Virology</i> , 2012, 86, 8452-8460.	1.5	36

#	ARTICLE	IF	CITATIONS
37	Diverse p63 and p73 isoforms regulate $\Delta 133p53$ expression through modulation of the internal TP53 promoter activity. <i>Cell Death and Differentiation</i> , 2012, 19, 816-826.	5.0	48
38	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. <i>Cell Death and Differentiation</i> , 2011, 18, 1815-1824.	5.0	173
39	Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. <i>Cancer Gene Therapy</i> , 2011, 18, 2-11.	2.2	151
40	Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway. <i>Virology Journal</i> , 2011, 8, 285.	1.4	38
41	G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. <i>Carcinogenesis</i> , 2011, 32, 271-278.	1.3	186
42	p53 regulates the transcription of its $\Delta 133p53$ isoform through specific response elements contained within the TP53 P2 internal promoter. <i>Oncogene</i> , 2010, 29, 2691-2700.	2.6	60
43	$\Delta 160p53$ is a novel N-terminal p53 isoform encoded by $\Delta 133p53$ transcript. <i>FEBS Letters</i> , 2010, 584, 4463-4468.	1.3	110
44	p53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 391-406.	2.4	68
45	Recent advances in p53 research: an interdisciplinary perspective. <i>Cancer Gene Therapy</i> , 2009, 16, 1-12.	2.2	140
46	TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. <i>Journal of Medical Genetics</i> , 2009, 46, 766-772.	1.5	64
47	The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotype-phenotype correlations. <i>Biochemical Society Transactions</i> , 2009, 37, 527-533.	1.6	14
48	Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. <i>Cancer Letters</i> , 2008, 261, 21-25.	3.2	94